Literature DB >> 19027039

Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics.

Koichiro Nakahara1, Chiaki Wakasa-Morimoto, Masanori Kobayashi, Shigeru Miki, Takeshi Noshi, Takahiro Seki, Mikiko Kanamori-Koyama, Shinobu Kawauchi, Akemi Suyama, Toshio Fujishita, Tomokazu Yoshinaga, Edward P Garvey, Brian A Johns, Scott A Foster, Mark R Underwood, Akihiko Sato, Tamio Fujiwara.   

Abstract

Passage of HIV-1 in the presence of integrase inhibitors (INIs) generates resistant viruses that have mutations in the integrase region. Integrase-resistant mutations Q148K and Q148R were identified as primary mutations with the passage of HIV-1 IIIB in the presence of INIs S-1360 or S/GSK-364735, respectively. Secondary amino acid substitutions E138K or G140S were observed when passage with INI was continued. The role of these mutations was investigated with molecular clones. Relative to Q148K alone, Q148K/E138K had 2- and >6-fold increases in resistance to S-1360 and S/GSK-364735, respectively, and the double mutant had slightly better infectivity and replication kinetics. In contrast, Q148K/G140S and Q148R/E138K had nearly equivalent or slightly reduced fold resistance to the INI compared with their respective Q148 primary mutants, and had increases in infectivity and replication kinetics. Recovery of these surrogates of viral fitness coincided with the recovery of integration efficiency of viral DNA into the host cell chromosome for these double mutants. These data show that recovery of viral integration efficiency can be an important factor for the emergence and maintenance of INI-resistant mutations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19027039     DOI: 10.1016/j.antiviral.2008.10.007

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  26 in total

1.  In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.

Authors:  Masanori Kobayashi; Tomokazu Yoshinaga; Takahiro Seki; Chiaki Wakasa-Morimoto; Kevin W Brown; Robert Ferris; Scott A Foster; Richard J Hazen; Shigeru Miki; Akemi Suyama-Kagitani; Shinobu Kawauchi-Miki; Teruhiko Taishi; Takashi Kawasuji; Brian A Johns; Mark R Underwood; Edward P Garvey; Akihiko Sato; Tamio Fujiwara
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

2.  Clinical Use of Inhibitors of HIV-1 Integration: Problems and Prospects.

Authors:  S P Korolev; Yu Yu Agapkina; M B Gottikh
Journal:  Acta Naturae       Date:  2011-07       Impact factor: 1.845

3.  Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir.

Authors:  Mathieu Métifiot; Kasthuraiah Maddali; Alena Naumova; Xuemin Zhang; Christophe Marchand; Yves Pommier
Journal:  Biochemistry       Date:  2010-05-04       Impact factor: 3.162

4.  HIV Drug Resistance and the Advent of Integrase Inhibitors.

Authors:  Peter K Quashie; Thibault Mesplède; Mark A Wainberg
Journal:  Curr Infect Dis Rep       Date:  2013-02       Impact factor: 3.725

5.  Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations.

Authors:  Kristen N Andreatta; Derrick D Goodman; Michael D Miller; Kirsten L White
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

6.  Prevalent polymorphisms in wild-type HIV-1 integrase are unlikely to engender drug resistance to dolutegravir (S/GSK1349572).

Authors:  Cindy Vavro; Samiul Hasan; Heather Madsen; Joseph Horton; Felix DeAnda; Louise Martin-Carpenter; Akihiko Sato; Robert Cuffe; Shuguang Chen; Mark Underwood; Garrett Nichols
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

Review 7.  HIV resistance to raltegravir.

Authors:  Francois Clavel
Journal:  Eur J Med Res       Date:  2009-11-24       Impact factor: 2.175

8.  Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.

Authors:  Michael E Abram; Rebecca M Hluhanich; Derrick D Goodman; Kristen N Andreatta; Nicolas A Margot; Linda Ye; Anita Niedziela-Majka; Tiffany L Barnes; Nikolai Novikov; Xiaowu Chen; Evguenia S Svarovskaia; Damian J McColl; Kirsten L White; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

9.  A dynamic model of HIV integrase inhibition and drug resistance.

Authors:  Alex L Perryman; Stefano Forli; Garrett M Morris; Catherine Burt; Yuhui Cheng; Michael J Palmer; Kevin Whitby; J Andrew McCammon; Chris Phillips; Arthur J Olson
Journal:  J Mol Biol       Date:  2010-01-22       Impact factor: 5.469

Review 10.  Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors.

Authors:  Erik Serrao; Srinivas Odde; Kavya Ramkumar; Nouri Neamati
Journal:  Retrovirology       Date:  2009-03-05       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.